Loss of RARRES3 is a key driver of lung metastasis in estrogen receptor-positive breast cancer, and the activation of RARRES3 is considered a useful therapeutic strategy for bladder cancer [50,51]. Here, ESR1 is linked to urinary bladder carcinoma.